澳大利亚全国范围内使用居家血斑采样进行胰岛自身抗体筛查:Type1Screen的2年结果
Type1Screen为有1型糖尿病家族史的澳大利亚人提供胰岛自身抗体检测,旨在预防糖尿病酮症酸中毒并启用疾病修饰治疗。分析2,064名注册者中1,243名已检测样本,比较血斑与静脉采血筛查的基线和结局;血斑筛查可行且能识别预期患病率,12例临床糖尿病均筛查阳性且无DKA。
要点
- 居家血斑筛查可行,尤其适合年轻和偏远地区参与者。
- 血斑筛查识别出多抗体阳性2.1%和单抗体阳性2.5%的预期患病率。
- 12例临床糖尿病均筛查阳性,无DKA发生。
核心结论
- Type1Screen具有全国覆盖范围;居家血斑筛查可行,尤其对居住在偏远地区的年轻参与者,并能识别临床前T1D的预期患病率。
研究设计与样本
- 分析2022年7月至2024年6月注册的2,064名参与者数据,其中1,507人选择血斑筛查、557人选择静脉采血筛查。
- 比较截至2024年6月已检测样本的1,243名参与者(血斑967人、静脉采血276人)的基线特征和结局。
主要发现
- 血斑筛查注册者中位年龄较低(12.1 [7.1, 27.1]岁 vs 17.2 [9, 38.4]岁;P < 0.0001),居住在澳大利亚偏远地区的比例较高(39% vs 29%;P = 0.0037)。
- 72名参与者(5.9%)筛查阳性,其中血斑筛查5人和静脉采血筛查2人确认试验无自身抗体。
- 血斑筛查识别出多抗体阳性患病率2.1%和单抗体阳性患病率2.5%,静脉采血筛查分别为1.5%和4.1%。
- 12名参与者发生临床糖尿病,均筛查阳性且无DKA。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type1Screen offers islet autoantibody testing to Australians with a family history of type 1 diabetes (T1D) with the dual aims of preventing diabetic ketoacidosis (DKA) and enabling use of disease-modifying therapy. We describe screening and monitoring outcomes 2 years after implementing in-home capillary blood spot sampling. RESEARCH DESIGN AND METHODS: Data from 2,064 participants who registered between July 2022 and June 2024 were analyzed: 1,507 and 557 chose blood spot and venipuncture screening respectively. We compared baseline characteristics and outcomes for 1,243 participants (967 blood spot and 276 venipuncture) whose samples were tested by June 2024. RESULTS: One blood spot and five venous participants reported unsuccessful sample collections. The median (quartile 1, quartile 3) age of blood spot registrants was lower (12.1 [7.1, 27.1] vs. 17.2 [9, 38.4] years; P < 0.0001), and a higher proportion lived in regional Australia (39% vs. 29%; P = 0.0037). Among 72 participants (5.9%) with a positive screening test, 5 screened by blood spot and 2 by venipuncture had no autoantibodies on confirmatory testing. Blood spot screening identified the expected 2.1% prevalence of multiple autoantibodies and a 2.5% prevalence of a single autoantibody compared with 1.5% and 4.1%, respectively, for venipuncture screening. Clinical diabetes developed in 12 participants. All had screened positive and none had DKA. CONCLUSIONS: Type1Screen has national reach. In-home blood spot screening is feasible, particularly for younger participants living regionally, and identifies the expected prevalence of preclinical T1D. The lower cost, increased convenience, and greater reach of blood spot screening could help meet increasing demand for early T1D diagnosis.
引用
- Wentworth JM, Sing ABE, Naselli G, et al. Islet Autoantibody Screening Throughout Australia Using In-Home Blood Spot Sampling: 2-Year Outcomes of Type1Screen. Diabetes Care. 2025. PMID: 39879258. doi:10.2337/dc24-2443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。